Filing Flows › Protalix BioTherapeutics (PLX) › GOODS revenue
Protalix BioTherapeutics (PLX) GOODS revenue by quarter
Protalix BioTherapeutics' GOODS revenue was $19.8M in Q2 2026 (second quarter 2026), +167% from Q1 2026. Over the last 7 quarters it ranged from $7.4M (Q1 2026) to $19.8M (Q2 2026).
| Quarter | GOODS revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $19.8M | +167% | +28% |
| Q1 2026 | $7.4M | -15% | -26% |
| Q4 2025 | $8.7M | -51% | -52% |
| Q3 2025 | $17.7M | +14% | — |
| Q2 2025 | $15.4M | +54% | — |
| Q1 2025 | $10.0M | -45% | — |
| Q4 2024 | $18.2M | — | — |
Q2 2026 at a glance
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' GOODS revenue?
Protalix BioTherapeutics' GOODS revenue was $19.8M in Q2 2026 (second quarter 2026), +167% from Q1 2026.
How has Protalix BioTherapeutics' GOODS revenue changed?
Over the last 7 quarters it ranged from $7.4M (Q1 2026) to $19.8M (Q2 2026).
Q2 2026 results → · How Protalix BioTherapeutics makes money →